financetom
Business
financetom
/
Business
/
i3 Verticals Shares Fall After Fiscal Q2 Miss, Fiscal Year Guidance Lowered
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
i3 Verticals Shares Fall After Fiscal Q2 Miss, Fiscal Year Guidance Lowered
May 10, 2024 12:14 PM

02:45 PM EDT, 05/10/2024 (MT Newswires) -- i3 Verticals ( IIIV ) shares fell more than 5% in recent Friday trading after the company reported fiscal Q2 results that missed market expectations and lowered its fiscal year 2024 guidance.

Earlier, the company reported fiscal Q2 adjusted earnings of $0.34 per diluted share, down from $0.38 a year earlier.

Analysts surveyed by Capital IQ expected $0.37.

Revenue for the quarter ended March 31 was $94.5 million, up from $93.9 million a year earlier.

Analysts surveyed by Capital IQ expected $98.5 million.

i3 Verticals ( IIIV ) expects fiscal 2024 adjusted EPS of $1.49 to $1.57, versus its prior outlook of $1.52 to $1.64. Analysts surveyed by Capital IQ expected $1.59.

The company expects revenue for the year of $380 million to $394 million, against $385 million to $400 million previously. Analysts expected $393.9 million.

Price: 20.99, Change: -1.18, Percent Change: -5.32

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Schrodinger Discontinues SGR-2921 Program Following Deaths of Two AML Patients
Schrodinger Discontinues SGR-2921 Program Following Deaths of Two AML Patients
Aug 14, 2025
07:51 AM EDT, 08/14/2025 (MT Newswires) -- Schrodinger (SDGR) said Thursday that it has discontinued its program for SGR-2921, which was intended to treat relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. The company said it made the decision after SGR-2921 was considered to have contributed to the deaths of two AML patients. Schrodinger said it believes the path to...
Beam Therapeutics Gets FDA Regenerative Medicine Status for BEAM-101 to Treat Sickle Cell Disease
Beam Therapeutics Gets FDA Regenerative Medicine Status for BEAM-101 to Treat Sickle Cell Disease
Aug 14, 2025
07:50 AM EDT, 08/14/2025 (MT Newswires) -- Beam Therapeutics ( BEAM ) said Thursday the US Food and Drug Administration has granted regenerative medicine advanced therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease. The company said that this designation is designed to support the development and evaluation of regenerative medicines,...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Weak Industrial Data Pours Cold Water on Eurozone's Hope for Industrial Recovery, Says ING
Weak Industrial Data Pours Cold Water on Eurozone's Hope for Industrial Recovery, Says ING
Aug 14, 2025
07:50 AM EDT, 08/14/2025 (MT Newswires) -- Thursday's macro data for the eurozone provides both a look in the rear-view mirror as well as a view through the side window, said INH. The picture the bank is seeing is one of fading industrial resilience and stark divergence across the eurozone. The look in the rear-view mirror shows a relatively resilient...
Copyright 2023-2026 - www.financetom.com All Rights Reserved